Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer
Disease control
Recruiting now
This trial is testing whether combining an antibody called naxitamab, the chemotherapy drug gemcitabine, and specially engineered natural killer (NK) cells from a healthy donor can safely shrink tumors in people with advanced HER2-negative breast cancer that has spread. The cance…
Phase: PHASE1, PHASE2 • Sponsor: Margaret Gatti-Mays • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC